Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EX 101 - Guangzhou Excelmab

X
Drug Profile

EX 101 - Guangzhou Excelmab

Alternative Names: EX-101 - Guangzhou Excelmab

Latest Information Update: 09 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Guangzhou Excelmab
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 20 Sep 2023 Guangzhou ExcelMab plans a phase III trial of EX 101 for Breast cancer and Gastric cancer in USA and China, in the first quarter of 2025 (Guangzhou ExcelMab pipeline, September 2023)
  • 11 Sep 2023 Guangzhou ExcelMab announces intention to submit BLA of EX 101 for Breast cancer and Gastric cancer in USA and China, in 2025 (Guangzhou ExcelMab pipeline, September 2023)
  • 11 Sep 2023 Guangzhou ExcelMab plans a phase II trial of EX 101 for Breast cancer and Gastric cancer in USA and China, by the end of 2023(Guangzhou ExcelMab pipeline, September 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top